Coronavirus Vaccine Update With Paul Offit – December 2, 2020
Coronavirus Vaccine Update With Paul Offit – December 2, 2020
With the Pfizer and Moderna coronavirus vaccines reportedly under review at the US FDA for emergency use authorization (EUA), Paul A. Offit, MD of the Children's Hospital of Philadelphia, returns to JAMA's Q&A series to provide an update on what to expect, prospects for vaccine rollout and distribution in the coming months, and ongoing safety surveillance. Recorded December 2, 2020.Check out our video explaining the vaccine frontrunners at https://youtu.be/KMc3vL_MIeo
Topics discussed in this interview:
0:00 Introduction
0:27 News from Pfizer and Moderna vaccine trials
2:06 Similarities between the two vaccines and results
3:10 What the results tell us about immunity
4:55 Data on diverse groups in clinical trials
6:14 Is there pressure to approve vaccine quickly
7:45 Vaccine safety
10:23 mRNA vaccines: safety and how they work
13:30 Data on children, pregnant women and autoimmune disease
15:03 Mandating vaccines
16:29 Should those in placebo groups be given access to the vaccines
17:26 Should those who had COVID-19 be vaccinated
18:25 Mandating vaccines
18:52 Can you receive two different types of vaccines
19:35 Can these vaccines cause long COVID
21:09 Vaccine timelines
23:01 When vaccine might be available for different groups
25:07 Educating people on adverse reactions to vaccines
26:40 Length of immunity
28:33 Genetic shift
29:39 This year for Dr Offit
• Earn Free CME credits by watching JAMA Livestreams and completing a brief questionnaire.
• Claim 0.5 credits for each video at https://ja.ma/covidqa
• Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt
• To watch all the #JAMALive Q&A's Visit: https://ja.ma/covidqaytpl
• Don't forget to hit subscribe or click https://ja.ma/subscribe
---------------------------------------------------------------------------------
For more from JAMA
• https://www.jama.com
• https://www.facebook.com/JAMAJournal
• https://www.twitter.com/JAMA_Current
• https://www.linkedin.com/company/jamanetwor
Follow the JAMA Network
• https://www.jamanetwork.com
• https://www.jamanetworkaudio.com
• https://www.facebook.com/JAMANetwork
• https://www.twitter.com/JAMANetwork
• https://www.instagram.com/JAMANetwork
• https://www.pinterest.com/JAMANetwork
=====================================================================
#JAMALive #Coronavirus #COVID19 #SARSCoV2 #Pandemic
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.